TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30876444

Group type: EXPERIMENTAL
Intervention: sIMRT (step-and-shoot intensity-modulated radiotherapy)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: dIMRT (dynamic intensity-modulated radiation therapy)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: VMAT (volumetric-modulated arc therapy)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tomo (helical tomotherapy)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All four radiotherapy modalities
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tomo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: sIMRT and dIMRT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All four approaches
Number of subjects: 10
Study: 30876459

Group type: COMPARATOR
Intervention: Pericardial closure using ECM in valve surgery
Number of subjects: 1420

Group type: COMPARATOR
Intervention: Pericardial closure using ECM in CABG surgery
Number of subjects: 1420

Group type: COMPARATOR
Intervention: Pericardial closure using ECM in both valve and CABG surgery
Number of subjects: 1420

Group type: COMPARATOR
Intervention: Postoperative atrial fibrillation in CABG patients
Number of subjects: 1420

Group type: COMPARATOR
Intervention: Postoperative atrial fibrillation in valve patients
Number of subjects: 1420
Study: 30876475

Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NLR)
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: NLR
Number of subjects: 938
Study: 30876480

Group type: EXPERIMENTAL
Intervention: Stool DNA-based SDC2 methylation test (meSDC2 LTE-qMSP)
Number of subjects: 585
Study: 30876830

Group type: EXPERIMENTAL
Intervention: Physiological tests including spirometry, body plethysmography, impulse oscillometry, and multiple breath nitrogen washout
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Impulse oscillometry and spirometry
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Acinar airway ventilation heterogeneity
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Physiological measures
Number of subjects: 872
Study: 30877130

Group type: EXPERIMENTAL
Intervention: Extensive scleral excision surgery (scleral window surgeries), removing 90% of the scleral thickness for 3 and 1/4 quadrants.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Extensive scleral excision surgery (scleral window surgeries)
Number of subjects: 5
Study: 30877202

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) therapy, administered via injections at weeks 0, 4, and 8
Number of subjects: 18
Study: 30877221

Group type: EXPERIMENTAL
Intervention: Modified Intermittent and Constant Osteoarthritis Pain (ICOAP) questionnaire
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Modified ICOAP-hand questionnaire
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Principal component analysis
Number of subjects: 300
Study: 30877569

Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg single-dose
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg twice daily
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Olaparib 200 mg twice daily
Number of subjects: 44
Study: 30877753

Group type: EXPERIMENTAL
Intervention: CD4 count ≥500 cells/µL
Number of subjects: 1901

Group type: COMPARATOR
Intervention: CD4 count 200-499 cells/µL
Number of subjects: 1901

Group type: COMPARATOR
Intervention: CD4 count <200 cells/µL
Number of subjects: 1901
Study: 30877780

Group type: EXPERIMENTAL
Intervention: eHealth self-management intervention for chronic pain
Number of subjects: 20
Study: 30878250

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30878319

Group type: EXPERIMENTAL
Intervention: Total body irradiation 400 cGy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Total body irradiation 200 cGy (previous standard)
Number of subjects: 17
Study: 30878406

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current use of point-of-care ultrasound
Number of subjects: 0
Study: 30878422

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) imaging-derived right ventricular (RV) strain
Number of subjects: 38
Study: 30878475

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 811
Study: 30878986

Group type: EXPERIMENTAL
Intervention: Visual field examinations in groups 1-6
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Visual field examinations in group 7
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Visual field examinations
Number of subjects: 80
Study: 30878987

Group type: EXPERIMENTAL
Intervention: Medicaid expansion
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Medicaid expansion
Number of subjects: 0
Study: 30879046

Group type: EXPERIMENTAL
Intervention: Preoperative spirometry with airflow obstruction defined as FEV1/FVC ratio below LLN
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Preoperative spirometry with FEV1 < LLN
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Prolonged cardiopulmonary bypass time
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Reduced kidney function
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: FEV1 < LLN
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Preoperative spirometry
Number of subjects: 551
Study: 30879050

Group type: EXPERIMENTAL
Intervention: Decellularized pulmonary homografts (DPH)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Combined DPH cohort (n=235)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Cryopreserved homografts (CH)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Bovine jugular vein (BJV)
Number of subjects: 121
Study: 30879249

Group type: EXPERIMENTAL
Intervention: AVXS-101
Number of subjects: 0
Study: 30879256

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 2550
Study: 30879511

Group type: EXPERIMENTAL
Intervention: Caesarean delivery
Number of subjects: 3792
Study: 30879757

Group type: EXPERIMENTAL
Intervention: Vertical Sleeve Gastrectomy (VSG)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 228
Study: 30879790

Group type: EXPERIMENTAL
Intervention: INCRAFT® AAA Stent Graft System
Number of subjects: 0
Study: 30879929

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced intra-operative ultrasound (CE-IOUS) using sulphur hexafluoride microbubbles
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intra-operative ultrasound (IOUS)
Number of subjects: 54
Study: 30879979

Group type: EXPERIMENTAL
Intervention: qHPV vaccine (three doses on Day 1, Month 2, Month 6)
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: qHPV vaccine
Number of subjects: 1030
Study: 30880509

Group type: EXPERIMENTAL
Intervention: Dot fertility app (Dynamic Optimal Timing)
Number of subjects: 718
Study: 30880554

Group type: EXPERIMENTAL
Intervention: Medical nutrition therapy program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30881101

Group type: EXPERIMENTAL
Intervention: Extensor training
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Flexor training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 54
Study: 30881102

Group type: EXPERIMENTAL
Intervention: Oliceridine 0.1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oliceridine 0.35 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oliceridine 0.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine 4 mg
Number of subjects: 0
Study: 30881452

Group type: EXPERIMENTAL
Intervention: Intramuscular neridronate (25 mg IM once a month for 6 years)
Number of subjects: 60
Study: 30881909

Group type: EXPERIMENTAL
Intervention: Fractionated-dose spinal anesthesia injection
Number of subjects: 42

Group type: COMPARATOR
Intervention: Single-dose spinal anesthesia injection
Number of subjects: 42
Study: 30881948

Group type: EXPERIMENTAL
Intervention: Cerebral oxygenation monitoring during intubation
Number of subjects: 0
Study: 30882062

Group type: EXPERIMENTAL
Intervention: Maternal surveys including diet, child temperament, family environment, and child care at 6 weeks, 3, 12, 18, 24, 36, 48, and 60 months.
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Child's birth weight and intent to breastfeed collected at 1-week home visit.
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Stool samples of the child collected at each visit, saliva at 1 visit.
Number of subjects: 468
Study: 30882240

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30882352

Group type: EXPERIMENTAL
Intervention: Mobile-based mindfulness and social support program
Number of subjects: 37
Study: 30882360

Group type: EXPERIMENTAL
Intervention: Triggered Escalating Real-Time Adherence (TERA) intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 120
Study: 30882400

Group type: EXPERIMENTAL
Intervention: Pre-operative blood sampling for DNA analysis and questionnaires sent at the third and sixth month after surgery.
Number of subjects: 561
Study: 30882905

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: SAVR with delirium
Number of subjects: 187

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 187
Study: 30883492

Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Canalith repositioning maneuvers
Number of subjects: 0
Study: 30883662

Group type: EXPERIMENTAL
Intervention: AdV-tk at doses of 1 × 10^11 and 3 × 10^11 vector particles (vp) injected into the tumor bed followed by 14 days of valacyclovir.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: AdV-tk at dose level 2.
Number of subjects: 8
Study: 30883668

Group type: EXPERIMENTAL
Intervention: Post-operative pain treatment (various analgesic treatments used, including morphine)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Intravenous morphine consumption
Number of subjects: 501
Study: 30885132

Group type: EXPERIMENTAL
Intervention: Fried Phenotype
Number of subjects: 1940

Group type: EXPERIMENTAL
Intervention: Frailty Trait Scale - short version
Number of subjects: 1940

Group type: EXPERIMENTAL
Intervention: SHARE-FI
Number of subjects: 1940

Group type: EXPERIMENTAL
Intervention: 35-Items Rockwood Frailty Index
Number of subjects: 1940

Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale
Number of subjects: 1940

Group type: EXPERIMENTAL
Intervention: FRAIL scale
Number of subjects: 1940

Group type: EXPERIMENTAL
Intervention: Gérontopôle Frailty Screening Tool
Number of subjects: 1940

Group type: EXPERIMENTAL
Intervention: Phone call at 6 months
Number of subjects: 1940
Study: 30885203

Group type: COMPARATOR
Intervention: Healthy subjects (n=36)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Type 2 diabetic patients (n=19)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Essential hypertensive patients (n=9)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Non-diabetic hypertensive subjects (n=10)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Hypertensive patients (n=9)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 73

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 73
Study: 30885222

Group type: EXPERIMENTAL
Intervention: Kidney patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy individuals (controls)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Increased sodium excretion and plasma sodium
Number of subjects: 24
Study: 30885327

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus chemotherapy (carboplatin and etoposide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 30885354

Group type: EXPERIMENTAL
Intervention: Radical consolidative treatment (RCT)
Number of subjects: 37
Study: 30885684

Group type: EXPERIMENTAL
Intervention: Microvascular Disease assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30885996

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Ponatinib
Number of subjects: 531
Study: 30886935

Group type: EXPERIMENTAL
Intervention: birth environment room
Number of subjects: 680

Group type: COMPARATOR
Intervention: standard room
Number of subjects: 680
Study: 30886950

Group type: EXPERIMENTAL
Intervention: Immediate Group - technology-enabled counselling intervention including education and counselling by a physical therapist, use of Fitbit and FitViz application, and 4 biweekly follow-up calls from the PT.
Number of subjects: 130

Group type: COMPARATOR
Intervention: Delayed Group - same program as Immediate Group starting in Week 10.
Number of subjects: 130
Study: 30886963

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (patients with RA treated with DMARD or healthy controls)
Number of subjects: 124
Study: 30886964

Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg/day for 12 months
Number of subjects: 15
Study: 30886974

Group type: EXPERIMENTAL
Intervention: Ixekizumab (high-affinity monoclonal antibody targeting interleukin-17A)
Number of subjects: 0
Study: 30886979

Group type: EXPERIMENTAL
Intervention: Psoriasis patients self-reporting PsA
Number of subjects: 0

Group type: COMPARATOR
Intervention: PsA established by a HCP
Number of subjects: 0
Study: 30886990

Group type: EXPERIMENTAL
Intervention: Modified Pilates exercises, treated twice a week for eight weeks.
Number of subjects: 98

Group type: COMPARATOR
Intervention: Aerobic exercises on treadmills or stationary bikes, treated twice a week for eight weeks.
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Modified Pilates exercises and Aerobic exercises (both groups), evaluated at baseline, eight weeks, six months, and 12 months after randomization.
Number of subjects: 98
Study: 30887180

Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg (twice daily) as monotherapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Olaparib 100 mg (twice daily) as monotherapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Olaparib 100 mg (twice daily) in combination with paclitaxel (80 mg/m weekly)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination treatment (Olaparib + Paclitaxel)
Number of subjects: 36
Study: 30887189

Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Vitamin K Antagonists (VKAs)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Practitioners at hospitals or mixed practices and specialists
Number of subjects: 141
Study: 30887269

Group type: EXPERIMENTAL
Intervention: CFAbd-Score (novel questionnaire)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: CFAbd-Score
Number of subjects: 116
Study: 30887820

Group type: EXPERIMENTAL
Intervention: Clinical trial setting (NCT00331773; NCT00004054)
Number of subjects: 7324
Study: 30887876

Group type: EXPERIMENTAL
Intervention: Guselkumab administered with a novel patient-controlled injector (One-Press)
Number of subjects: 0
Study: 30888024

Group type: EXPERIMENTAL
Intervention: KLRG1-Expressing CD4 T Cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment for tuberculosis
Number of subjects: 0
Study: 30888111

Group type: EXPERIMENTAL
Intervention: Predictive model for risk of variceal bleeding comprising of grade 2-3 esophageal varices, red spots, and fibrinogen level <150 mg/dL
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Platelet aggregation analysis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fibrinogen level, adenosine diphosphate, and thrombin-dependent platelet aggregation
Number of subjects: 20
Study: 30888325

Group type: EXPERIMENTAL
Intervention: Mobile exercise app
Number of subjects: 12
Study: 30888398

Group type: EXPERIMENTAL
Intervention: Circadian melatonin rhythm in girls with PCOS
Number of subjects: 92

Group type: COMPARATOR
Intervention: Circadian melatonin rhythm in control subjects
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Morning circadian misalignment
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Circadian misalignment in girls with PCOS
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Clinical care recommendations
Number of subjects: 92
Study: 30888551

Group type: EXPERIMENTAL
Intervention: Autism Behavior Inventory (ABI)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: ABI
Number of subjects: 144
Study: 30889492

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil at recommended dose (RD) of 35 mg/m² in combination with oxaliplatin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil
Number of subjects: 24
Study: 30890162

Group type: EXPERIMENTAL
Intervention: Remotely supervised transcranial direct current stimulation (RS-tDCS) administered daily (Monday - Friday) for a total of sixty sessions, 20 minutes of 2.5 mA direct current targeting the cerebellum, paired with cognitive training and physical exercises.
Number of subjects: 1
Study: 30890544

Group type: EXPERIMENTAL
Intervention: Plerixafor (240 µg/kg)
Number of subjects: 64
Study: 30890548

Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPU) using SonoCloud-1 device, activated monthly before intravenous carboplatin chemotherapy.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPU) using SonoCloud-1 device.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPU) using SonoCloud-1 device before carboplatin chemotherapy.
Number of subjects: 21
Study: 30890600

Group type: EXPERIMENTAL
Intervention: Fludarabine, cyclophosphamide, and rituximab (FCR) induction followed by 36 months of rituximab maintenance therapy
Number of subjects: 84
Study: 30890946

Group type: EXPERIMENTAL
Intervention: NU-AGE dietary intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hierarchical Bayesian Models
Number of subjects: 0
Study: 30891001

Group type: EXPERIMENTAL
Intervention: Electromyography
Number of subjects: 0
Study: 30891607

Group type: EXPERIMENTAL
Intervention: Intradermal delivery of INO-4201
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular delivery of INO-4201
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of INO-4201 and INO-4202 with interleukin-12
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intradermal delivery of INO-4202
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular delivery of INO-4202
Number of subjects: 0
Study: 30891696

Group type: EXPERIMENTAL
Intervention: Continuous electroencephalography (cEEG) recording initiated immediately after identification, median cEEG time per patient was 44 hours (interquartile range 21-99 hours).
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Continuous electroencephalography (cEEG) recording initiated immediately after identification.
Number of subjects: 102
Study: 30891962

Group type: EXPERIMENTAL
Intervention: Proximal Optimization Technique (POT)
Number of subjects: 1191

Group type: COMPARATOR
Intervention: Non-Proximal Optimization Technique (non-POT)
Number of subjects: 1191
Study: 30891964

Group type: EXPERIMENTAL
Intervention: LBBB (Left Bundle Branch Block)
Number of subjects: 5157

Group type: EXPERIMENTAL
Intervention: NICD (Nonspecific Intraventricular Conduction Delay)
Number of subjects: 5157

Group type: EXPERIMENTAL
Intervention: RBBB (Right Bundle Branch Block)
Number of subjects: 5157

Group type: COMPARATOR
Intervention: Narrow QRS
Number of subjects: 5157

Group type: EXPERIMENTAL
Intervention: LBBB
Number of subjects: 5157

Group type: EXPERIMENTAL
Intervention: NICD
Number of subjects: 5157

Group type: EXPERIMENTAL
Intervention: RBBB
Number of subjects: 5157
Study: 30892988

Group type: EXPERIMENTAL
Intervention: Venetoclax 600 mg per day orally in 28-day cycles plus low-dose cytarabine (LDAC) 20 mg/m²
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Venetoclax plus LDAC in patients without prior HMA exposure
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 82
Study: 30894288

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (TMVr)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 614
Study: 30895121

Group type: EXPERIMENTAL
Intervention: CAF + ADM + PRP
Number of subjects: 12

Group type: COMPARATOR
Intervention: CAF + ADM
Number of subjects: 12
Study: 30895237

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa 150 μg
Number of subjects: 400

Group type: COMPARATOR
Intervention: Follitropin beta 300 IU/day
Number of subjects: 400
Study: 30895238

Group type: EXPERIMENTAL
Intervention: Modified Beckman Coulter Gen II ELISA assay (Premix method)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Beckman Coulter Gen II ELISA original assay (Gen II original)
Number of subjects: 269
Study: 30895236

Group type: EXPERIMENTAL
Intervention: Endometrial biopsy during the follicular phase (on the sixth to eighth day of exogenous stimulation)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Endometrial biopsy during the follicular phase
Number of subjects: 360
Study: 30895243

Group type: EXPERIMENTAL
Intervention: s.c. progesterone for luteal phase support
Number of subjects: 0

Group type: COMPARATOR
Intervention: vaginal progesterone for luteal phase support
Number of subjects: 0
Study: 30895244

Group type: EXPERIMENTAL
Intervention: 0.5 mL insemination volume
Number of subjects: 269

Group type: COMPARATOR
Intervention: 0.2 mL insemination volume
Number of subjects: 269
Study: 30895467

Group type: EXPERIMENTAL
Intervention: LADA patients with high-titer GADA
Number of subjects: 54

Group type: COMPARATOR
Intervention: LADA patients with low-titer GADA
Number of subjects: 54
Study: 30895945

Group type: EXPERIMENTAL
Intervention: Charge density (CD) mapping
Number of subjects: 0

Group type: COMPARATOR
Intervention: Voltage measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ablation of critical points
Number of subjects: 0
Study: 30896220

Group type: EXPERIMENTAL
Intervention: Delay discounting
Number of subjects: 202